The University of Chicago Header Logo

Connection

Stephen Hanauer to Drug Therapy, Combination

Back to Details
This is a "connection" page, showing publications Stephen Hanauer has written about Drug Therapy, Combination.
Stephen Hanauer
Connection Strength
1.556
Drug Therapy, Combination
  1. Medical management of Crohn's disease: treatment algorithms 2009. Dig Dis. 2009; 27(4):536-41.
    View in: PubMed
    Score: 0.269
  2. EXPLORing the Therapeutic Ceiling in Crohn's Disease: Will Combination Pave the Way? Clin Gastroenterol Hepatol. 2024 Jul; 22(7):1377-1378.
    View in: PubMed
    Score: 0.178
  3. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42.
    View in: PubMed
    Score: 0.124
  4. Optimizing pharmacologic management of inflammatory bowel disease. Expert Rev Clin Pharmacol. 2017 Jun; 10(6):595-607.
    View in: PubMed
    Score: 0.113
  5. Heading back to the trough (levels of biologics in IBD). Clin Gastroenterol Hepatol. 2015 Mar; 13(3):548-51.
    View in: PubMed
    Score: 0.095
  6. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. Am J Med. 2011 Apr; 124(4 Suppl):e1-18.
    View in: PubMed
    Score: 0.074
  7. Devolving therapeutic pyramids. Nat Rev Gastroenterol Hepatol. 2010 Mar; 7(3):119-20.
    View in: PubMed
    Score: 0.069
  8. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8.
    View in: PubMed
    Score: 0.065
  9. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007 Sep; 56(9):1181-3.
    View in: PubMed
    Score: 0.058
  10. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007 Jan; 13(1):2-11.
    View in: PubMed
    Score: 0.055
  11. Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. Inflamm Bowel Dis. 2025 Oct 01; 31(10):2714-2724.
    View in: PubMed
    Score: 0.051
  12. Immunogenicity of infliximab in Crohn's disease. N Engl J Med. 2003 May 22; 348(21):2155-6; author reply 2155-6.
    View in: PubMed
    Score: 0.043
  13. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(2):81-92.
    View in: PubMed
    Score: 0.042
  14. Updating the approach to Crohn's disease. Hosp Pract (1995). 1999 Aug 15; 34(8):77-8, 81-3, 87-93; discussion 94.
    View in: PubMed
    Score: 0.033
  15. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999 Jun; 94(6):1587-92.
    View in: PubMed
    Score: 0.033
  16. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1.
    View in: PubMed
    Score: 0.031
  17. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). Aliment Pharmacol Ther. 2018 Apr; 47(8):1092-1102.
    View in: PubMed
    Score: 0.030
  18. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22; 369(8):699-710.
    View in: PubMed
    Score: 0.022
  19. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21.
    View in: PubMed
    Score: 0.022
  20. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
    View in: PubMed
    Score: 0.021
  21. Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol. 2013 Jan; 47(1):52-7.
    View in: PubMed
    Score: 0.021
  22. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci. 2012 Jan; 57(1):250-3.
    View in: PubMed
    Score: 0.019
  23. Sulfasalazine vs. steroids in Crohn's disease: David vs. Goliath? Gastroenterology. 1991 Oct; 101(4):1130-1.
    View in: PubMed
    Score: 0.019
  24. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213.
    View in: PubMed
    Score: 0.018
  25. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2007 Sep; 45(3):312-8.
    View in: PubMed
    Score: 0.014
  26. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50.
    View in: PubMed
    Score: 0.014
  27. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007 Sep; 56(9):1232-9.
    View in: PubMed
    Score: 0.014
  28. Acute leukemia following inflammatory bowel disease. Dig Dis Sci. 1982 Jun; 27(6):545-8.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.